[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urge-urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urge-urinary-incontinence":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,67,97,132,171,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100628071","post-approval-effectiveness-and-durability-evaluation-of-the-altaviva-tibial-device-100628071",false,"NCT07456865","Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device","ENDURANCE™","Inclusion Criteria:\n\n1. Candidate for Altaviva™ therapy per Altaviva™ labeling\n2. Have a diagnosis of UUI as demonstrated on a 3-day voiding diary by having a minimum of 3 episodes of urinary urge incontinence in 72 hours\n3. If taking OAB medications, subjects should be on a stable dose for at least 3 months prior to baseline and willing to remain on stable treatment through completion of the 12-month voiding diary\n4. Patient must be willing and able to accurately complete study questionnaires, attend visits, operate the system, and comply with the study protocol\n5. Willing and able to provide signed and dated informed consent\n\nExclusion Criteria:\n\n1. Patient who is not a candidate for Altaviva™ therapy per Altaviva™ labeling, including:\n\n   * Patients who are considered to be poor surgical candidates or who are at risk for poor wound healing per Altaviva™ labeling\n   * Have progressive, systemic neurological disease\n   * Have clinically significant peripheral neuropathy in the lower leg\n   * Severe, uncontrolled diabetes\n2. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component based on physician judgment\n3. Current symptomatic urinary tract infection\n4. Patients who have been treated with percutaneous tibial nerve stimulation (PTNS)\u002Fpercutaneous tibial neuromodulation (PTNM) therapy in the past 4 weeks, or longer if the investigator judges that the therapeutic effect is still present\n5. Patients who have had treatment of urinary symptoms with botulinum toxin therapy or sacral neuromodulation in the past 6 months\n6. History of a prior implantable tibial neuromodulation system\n7. Patients who are pregnant or planning to become pregnant during the course of the study\n8. Patient is currently enrolled or plans to enroll in concurrent drug\u002Fdevice study that may confound study results","ALL","18 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI",[26],"Urge Urinary Incontinence","RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2026-03-17",{"date":35,"type":20},"2032-11",{"name":37,"class":38},"MedtronicNeuro","INDUSTRY",8,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100584176","augmenting-urinary-reflex-activity-study-4-including-extended-indications-100584176","NCT06885931","Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)","Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System","AURA-4X","Inclusion Criteria:\n\n* Female. NB: the definition of female refers to sex at birth.\n* Adult: aged ≥ 22 years (at the time of informed consent signature).\n* Patient self-reports both stress and urge episodes (clinician-opinion on history taking).\n* Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.\n* Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.\n* Able and willing to voluntarily sign informed consent form.\n* Able to participate in all testing and follow-up clinic visits associated with study protocol.\n* Patient is mobile and able to use a toilet.\n* In the opinion of the Investigator, the patient is capable of independently using the system components (after training).\n\nExclusion Criteria:\n\n* Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.\n* Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.\n* In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.\n* Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.\n* History of major psychiatric or personality disorder.\n* Any neurological condition that in the opinion of the investigator may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or complete spinal cord injury).\n* Uncontrolled type I or type II diabetes (as defined by their routine care clinician or HBA1C ≥ 7.0).\n* History of cancer within 5 years prior to enrolment, except for a cancer that was determined to be free of systemic cancer risk, such as basal cell carcinoma.\n* Patient is taking antiplatelet and\u002For anticoagulant drugs including warfarin or newer alternatives (e.g., rivaroxaban, apixaban, dabigatran, edoxaban) which cannot be paused prior to surgery, or has a bleeding disorder that cannot be corrected prior to surgery.\n* Any clinical reason that, in the opinion of the Investigator, may compromise patient's safety during the study.\n* Currently participating in another interventional study. This excepts purely observational studies, e.g., registries.\n* Patient participation in vigorous physical activities where these cannot be restricted for a period of 6 weeks post-implantation.\n* Patient unwilling to stop any future participation in scuba diving below 10m. BMI ≥ 40kg\u002Fm2 or waist circumference \\> 127cm\n* Documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone.\n* Skin, orthopedic or neurological anatomical limitations at the site of implant that could prevent successful placement of an electrode or IPG. This includes active perineal sepsis or perianal sepsis (e.g., anal fistula and pilonidal sinus).\n* Knowledge of planned MRIs, diathermy, medical microwave exposure, high output ultrasonic exposure, or medical RF energy exposure.\n* Implantable neurostimulator or antennae, pacemaker or defibrillator in-situ (anywhere in body).\n\nExclusion Criteria (Urological):\n\n* Known diagnosis of interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines. Diagnosis of any other chronic pelvic or regional pain syndrome\n* Documented bladder emptying syndrome including neurogenic bladder.\n* Known abnormal post void residual (\\> 100 ml).\n* Any prolapse (symptomatic or asymptomatic) currently at or below the hymenal level Known urinary tract mechanical obstruction such as urethral stricture and\u002For bladder neck contracture.\n* Current symptomatic urinary tract infection (UTI) or more than 3 culture-proven UTIs in past year.\n* Current diagnosis of vesicoureteral reflux\n* Current diagnosis of bladder stones\n* History of bladder tumour (benign or malignant) -Suspected or proven pudendal nerve entrapment syndrome. In patients with co- existent chronic pelvic pain and urinary incontinence symptoms, Nantes criteria will be used for screening. Patients meeting essential criteria will be excluded from the study.\n* Suspected or proven severe pudendal nerve damage at discretion of clinician with or without specialist investigations\n* Any previous experience of pudendal nerve stimulation using an implanted lead.\n* Previous failure of SNM therapy (based on implantation; failed test phase is not an exclusion)\n* Major previous urethral or bladder surgery (excisional or reconstructive) at discretion of investigator\n* SUI surgery e.g. urethral slings, tapes, and bulking agents colposuspension within last 2 years; \\> 2 years at discretion of investigator\n* Prolapse surgery e.g. colposuspension \u002F colporrhaphy within last 12 months with current confirmation via pelvic exam of no recurrence \\> or = to Stage 2 pelvic organ prolapse\n* Previous use of bladder botox injections within last 6 months","FEMALE","22 Years",{"count":51,"type":20},86,[23],"Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.",[55,56,57,26],"Mixed Urinary Incontinence","Stress Urinary Incontinence (SUI)","Chronic Pelvic Pain","2026-05-13",{"date":60,"type":31},"2026-05-15",{"date":62,"type":31},"2025-06-24",{"date":64,"type":20},"2030-01",{"name":66,"class":38},"Amber Therapeutics Ltd",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100634165","comparative-efficacy-of-electromagnetic-field-therapy-and-tibial-nerve-stimulation-in-urge-urinary-incontinence-100634165","NCT07536139","COMPARATIVE EFFICACY OF ELECTROMAGNETIC FIELD THERAPY AND TIBIAL NERVE STIMULATION IN URGE URINARY INCONTINENCE","COMPARISON OF MAGNETIC FIELD THERAPY AND TIBIAL NERVE STIMULATION IN WOMEN WITH URGE URINARY INCONTINENCE: A PROSPECTIVE, RANDOMIZED, ASSESSOR-BLINDED CLINICAL TRIAL","Inclusion Criteria:\n\n* Female participants aged 18-65 years Diagnosis of urge urinary incontinence based on clinical evaluation Presence of urinary urgency with or without urge incontinence episodes Ability to understand and complete questionnaires Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\nPredominant stress urinary incontinence or mixed incontinence with stress predominance Neurological diseases affecting bladder function (e.g., multiple sclerosis, spinal cord injury, Parkinson's disease) Active urinary tract infection History of pelvic surgery affecting urinary function Pregnancy or breastfeeding Use of medications affecting bladder function (unless stable for at least 4 weeks) Presence of implanted electronic devices (e.g., pacemaker) Severe cognitive impairment preventing participation Participation in another clinical trial within the last 3 months\n\n\\-","80 Years",{"count":76,"type":20},40,[23],"Urge urinary incontinence is a prevalent condition characterized by involuntary leakage of urine accompanied by a sudden, compelling urge to void. It significantly impairs quality of life and is associated with substantial physical, psychological, and social burden. Noninvasive treatment modalities, including pulsed electromagnetic field (PEMF) therapy and posterior tibial nerve stimulation (PTNS), have gained attention due to their safety and ease of application.\n\nThis study is designed as a prospective, randomized, assessor-blinded clinical trial conducted in women diagnosed with urge urinary incontinence. Eligible participants will be randomly assigned to one of two intervention groups: PEMF therapy or tibial nerve stimulation. Both interventions will be applied over a predefined treatment period under standardized conditions.\n\nOutcome measures will include symptom severity, frequency of incontinence episodes, and quality of life, assessed using validated instruments such as the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), bladder diaries, and quality-of-life scales. Assessments will be performed at baseline and after completion of the treatment period.\n\nThe primary aim of the study is to compare the efficacy of PEMF therapy and tibial nerve stimulation in reducing urinary symptoms. Secondary objectives include evaluating improvements in quality of life and functional outcomes. The findings of this study are expected to contribute to the optimization of noninvasive treatment strategies for urge urinary incontinence.",[26],[26,81,82,83,84],"Pulsed Electromagnetic Field Therapy","Posterior Tibial Nerve Stimulation","ICIQ-UI SF","Women's Health","NOT_YET_RECRUITING","2026-04-11",{"date":88,"type":31},"2026-04-17",{"date":90,"type":20},"2026-04",{"date":92,"type":20},"2027-04",{"name":94,"class":95},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":74,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100609041","detrusor-nerve-radiofrequency-ablation-for-overactive-bladder-in-women-100609041","NCT07209397","Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women","A Randomized, Prospective, Multicenter, Double-Blind, Sham-Controlled Study to Assess the MORPHEUSV Radiofrequency (RF) Device in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB) With Urge Incontinence and\u002For Urge-Predominant Mixed Incontinence","DENARA","INCLUSION CRITERIA:\n\n* Female, aged 22 to 80 years inclusive at the time of consent.\n* History of idiopathic overactive bladder (OAB) symptoms for ≥6 months.\n* At least 7 episodes of urge urinary incontinence (UUI) over 3 days, as recorded in a 3-day bladder diary during screening.\n* Urge-predominant incontinence, defined as greater number of UUI episodes than stress urinary incontinence (SUI) episodes during screening.\n* Willing and able to complete the 3-day bladder diary.\n* Willing to discontinue OAB medications (e.g., anticholinergics, beta-3 agonists) at least 2 weeks prior to baseline treatment visit, if currently taking such medications.\n* Willing to use a reliable method of contraception during the study period, if of childbearing potential and sexually active.\n* Negative pregnancy test at screening (if applicable).\n* Willing and able to provide written informed consent and comply with study procedures and follow-up schedule.\n\nEXCLUSION CRITERIA:\n\n* Predominant stress urinary incontinence (SUI) based on bladder diary\n* Currently pregnant, breastfeeding, or planning pregnancy during the study\n* History of neurologic conditions affecting bladder function (e.g., multiple sclerosis, spinal cord injury, Parkinson's disease)\n* Active urinary tract infection (UTI) at screening\n* History of interstitial cystitis, bladder pain syndrome, or chronic pelvic pain\n* Prior or current bladder cancer, pelvic malignancy, or pelvic radiation\n* Pelvic organ prolapse beyond the hymen (POP-Q stage \\> II)\n* Implanted neuromodulation device or prior sacral nerve stimulation\n* Use of bulking agents, Botox, or surgical treatment for incontinence within 12 months\n* Prior pelvic floor RF treatment or laser vaginal rejuvenation\n* Significant pelvic anatomical abnormalities that interfere with treatment\n* Use of investigational drug or device within 30 days before screening\n* Any condition that, in the investigator's opinion, would interfere with safe study participation or data integrity\n* Uncontrolled systemic disease (e.g., uncontrolled diabetes, cardiovascular disease)\n* Inability or unwillingness to comply with study requirements or follow-up",{"count":106,"type":20},202,[23],"The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.",[110,111,26,112,55,113,114],"Overactive Bladder","Overactive Bladder (OAB)","Mixed Urinary Incontinence (Urge-Predominant)","Idiopathic Overactive Bladder With Urinary Incontinence","Idiopathic Overactive Bladder",[116,117,118,119,120,121],"Overactive bladder","Urge urinary incontinence","Mixed urinary incontinence","Female urinary symptoms","urogynecology","Female Urology","2026-01-28",{"date":124,"type":31},"2026-01-30",{"date":126,"type":31},"2025-11-25",{"date":128,"type":20},"2027-11-30",{"name":130,"class":38},"InMode MD Ltd.",9,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":48,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":152,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":96},"100606457","pelvic-floor-disorder-symptoms-in-women-seeking-weight-loss-therapy-100606457","NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","Inclusion Criteria:\n\n* female\n* 18-89 years old\n* any race\u002Fethnicity\n* BMI ≥30 kg\u002Fm2\n* current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \\& Bariatric Surgery\n* able\u002Fwilling to give informed consent\n* have a home scale to measure weight\n\nPatients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:\n\n* prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1\u002Fgastric inhibitory peptide (GIP1)\n* taking other weight loss agents (such as metformin)\n\nPatients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:\n\n* plan to undergo gastric sleeve or gastric bypass surgery\n* taking weight loss agents which are not GLP-1 RA or GLP-1\u002FGIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1\u002FGIP1 medications after surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* ≥90 years old\n* \\\u003C18 years old\n* BMI \\\u003C30 kg\u002Fm2\n* A history of bariatric surgery prior to enrollment\n* No home scale to measure weight\n* Active cancer",true,"90 Years",{"count":141,"type":20},200,"OBSERVATIONAL","The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.",[145,146,26,110,147,148,149,150,151],"Lower Urinary Tract Symptoms","Stress Urinary Incontinence","Pelvic Organ Prolapse","Weight Loss","Fecal Incontinence","Bariatric Surgery","glp1 Agonist",[153,154,155,156,157,158,159,160,161],"lower urinary tract symtpoms","stress urinary incontinence","urge urinary incontinence","overactive bladder","pelvic organ prolapse","weight loss","fecal incontinence","bariatric surgery","glp1 agonist","2025-09-15",{"date":164,"type":31},"2025-09-16",{"date":166,"type":20},"2025-10",{"date":168,"type":20},"2027-06",{"name":170,"class":95},"Hartford HealthCare",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":48,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":96},"100576290","effect-of-neuromodulation-and-therapeutic-exercise-in-urinary-incontinence-100576290","NCT06783374","Effect of Neuromodulation and Therapeutic Exercise in Urinary Incontinence","Effect of a Peripheral and Central Neuromodulation Protocol Combined With the Application of Therapeutic Exercise in Patients Diagnosed With Urinary Incontinence. A Randomized Control Trial (RCT)","UCV\u002FINCONTINEN","Inclusion Criteria:\n\n* Present with a diagnosis of urinary incontinence or overactive bladder\n* Women of menopausal age (\\>45 years)\n* ≥3 months of duration\n* Fulfill the established criteria for patient selection for neuromodulation treatment (urge urinary incontinence)\n* Speak native Spanish or English\n\nExclusion Criteria:\n\n* Prior or scheduled surgical procedures in the lumbar or abdominal region\n* Presence of fractures or severe pathological conditions\n* Current pregnancy or potential for pregnancy during the study period\n* Neurological or psychiatric disorders\n* Presence of stress urinary incontinence\n* Female subjects with autoimmune diseases or malignancies\n* Belonephobia\n* Subjects who have undergone previous neuromodulation","45 Years",{"count":181,"type":20},63,[23],"Urge urinary incontinence (UUI) is a component of the condition known as overactive bladder, a severe and debilitating chronic disorder affecting healthcare systems worldwide. The efficacy of therapeutic exercise and neuromodulation in the treatment of UUI is evaluated, and these techniques are combined.",[26,111],[186,187,188,189],"Menopause","exercise","Neuromodulation","Posterior tibial nerve","2025-04-10",{"date":192,"type":31},"2025-04-13",{"date":194,"type":31},"2025-03-04",{"date":196,"type":20},"2026-11-10",{"name":198,"class":95},"Fundación Universidad Católica de Valencia San Vicente Mártir",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":96},"100553217","optimal-injection-interval-for-intra-detrusor-botulinum-toxin-100553217","NCT06483217","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin: A Randomized Controlled Trial Utilizing a Patient-Centered Approach","Inclusion Criteria:\n\n* diagnosis of overactive bladder, detrusor overactivity, urinary urgency, urinary frequency, nocturnal polyuria, or urge urinary incontinence\n* pursuing treatment with intravesical botulinum toxin injections\n\nExclusion Criteria:\n\n\\- non-OAB diagnosis such as pelvic pain or interstitial cystitis",{"count":207,"type":20},100,[23],"The goal of this clinical trial is to see if patients deciding their own follow up times can increase the effectiveness of botulinum toxin (BTX or \"Botox\") injection for overactive bladder (OAB). The main questions it aims to answer are:\n\n* Does the time between repeat injections differ from the 6-month standard when it is based on patient symptoms alone?\n* Does symptom control or patient satisfaction change when patients control their own follow up times?\n\nParticipants will undergo standard botulinum toxin injection into the bladder for OAB treatment and will then be randomly assigned to follow up either at a standard 6-month interval or whenever they feel their symptoms return.",[110,211,212,26],"Urinary Urgency","Urinary Incontinence",[214,215,216,217,218,219,156,155,220],"intradetrusor botulinum toxin","intravesical botox","intradetrusor botox","bladder chemodenervation","botox","chemodenervation","intravesical botulinum toxin","2024-07-15",{"date":223,"type":31},"2024-07-17",{"date":225,"type":20},"2024-07",{"date":166,"type":20},{"name":228,"class":95},"Louisiana State University Health Sciences Center in New Orleans"]